Results 101 to 110 of about 10,181,415 (248)

Comparison between responders and non-responders.

open access: yes, 2018
Comparison between responders and non-responders.
David Armstrong (109098)   +3 more
core   +1 more source

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec   +6 more
wiley   +1 more source

Clinical characteristics of PIVKA-Ⅱ responders and non-responders.

open access: yes, 2022
Clinical characteristics of PIVKA-Ⅱ responders and non-responders.
Shun Kaneko (8735283)   +20 more
core   +1 more source

Influenza Vaccination Responses in Disabled Stroke Patients: A Single‐Center Prospective Observational Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to investigate the immunological response to influenza vaccination, the incidence and severity of influenza infection, and the side effects of the vaccination in patients with ischemic stroke. Methods This prospective observational study was conducted between 2023 and 2024 at Ramathibodi Hospital.
Achiraya Pakngao   +5 more
wiley   +1 more source

Comparison of responders and non-responders.

open access: yes, 2016
Comparison of responders and non-responders.
Imed Harrabi (2580121)   +6 more
core   +1 more source

The gut-brain-axis one year after treatment with cladribine tablets in patients with relapsing remitting multiple sclerosis: a pilot study

open access: yesFrontiers in Immunology
IntroductionCladribine tablets are an effective treatment for relapsing remitting multiple sclerosis (RRMS). However, almost half of the treated patients are not free of disease activity after two years.
Jeske van Pamelen   +12 more
doaj   +1 more source

Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro   +6 more
wiley   +1 more source

Minutes of the 5th meeting of the Council of the International Union of Immunological Societies

open access: yes, 1971
Council minutes from the fifth Council meeting of the International Union of Immunological Societies in Washington, D.C., U.S ...
International Union of Immunological Societies
core  

Characteristics of responders and non-responders.

open access: yes, 2018
Characteristics of responders and non-responders.
Maria Eveslage (3455072)   +4 more
core   +1 more source

The influence of extrinsic apoptosis gene expression on immunological reconstitution of male ART-treated PLHIV

open access: yesBMC Infectious Diseases
The primary goal of antiretroviral therapy (ART) is to suppress viral replication to undetectable levels (
Henrique Fernando Lopes-Araujo   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy